Pathology and Molecular Biology Center, National Cancer Hospital K, 30 Cau Buou Street, Thanh Tri, Hanoi, Viet Nam.
National Key Laboratory of Gene Technology, Institute of Biotechnology, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet Street, Cau Giay, Hanoi, Viet Nam.
Pathol Res Pract. 2020 Apr;216(4):152898. doi: 10.1016/j.prp.2020.152898. Epub 2020 Feb 17.
KRAS, NRAS, and BRAF are potential tumor-driven genes that are involved in the RAS/RAF/MAPK signaling pathway. RAS/RAF mutations importantly contribute to colorectal tumorigenesis since they remain the activated status of downstream pathways without regulation of the upstream EGFR signal. However, it has not been unclear how epigenetic alterations involved in colorectal tumorigenesis mediated by KRAS, NRAS, or BRAF mutations. Therefore, in this study, we investigated the frequency and distribution of KRAS/NRAS/BRAF mutations in Vietnamese colorectal cancer (CRC) and explored the relationship between genetic and epigenetic abnormalities in 156 tumors of CRC. Somatic mutations of KRAS (exon 2, codon 12/13; exon 3, codon 61), NRAS (exon 2, codon 12/13; exon 3, codon 61), and BRAF (exon 15, codon 600) was determined by Cobas® KRAS Mutation Test, Therascreen NRAS Pyro Kit and Cobas® 4800 BRAF V600 Mutation Test, respectively. Methylation status of BRCA1, MLH1, MGMT, p16, RASSF1A, and APC was detected by methylation-specific PCR. Distribution of each abnormality in clinicopathological features was also analyzed. Results showed the mutation rates of KRAS, NRAS, and BRAF were 41.0 %, 9.6 %, 8.3 % respectively, while the methylation rates of BRCA1, MLH1, MGMT, p16, RASSF1A, and APC were 16.7 %, 16.7 %, 32.7 %, 30.1 %, 30.1 %, and 37.2 % respectively. The distribution of KRAS mutation was mutually exclusive against that of NRAS (p < 0.001) and BRAF (p < 0.001) mutations in CRC. RAS/RAF mutations were more common in adenocarcinoma subtype (p = 0.020), whereas RASSF1A methylation was more frequent in mucinous adenocarcinoma subtype (p = 0.007). In addition, the frequency of having KRAS mutations was significantly higher in MGMT (p = 0.035) or RASSF1A (p = 0.043) methylated cases than in those without methylation. BRAF mutations were positively associated with MLH1 hypermethylation (p = 0.028) but were inversely associated with APC hypermethylation (p = 0.032). Overall, our results show specific interactions of genetic and epigenetic alterations and suggest the presence of independent oncogenic pathways in tumorigenesis of CRC.
KRAS、NRAS 和 BRAF 是潜在的肿瘤驱动基因,参与 RAS/RAF/MAPK 信号通路。RAS/RAF 突变重要地促成了结直肠癌的肿瘤发生,因为它们在没有上游 EGFR 信号调节的情况下保持下游途径的激活状态。然而,KRAS、NRAS 或 BRAF 突变介导的结直肠癌发生中的表观遗传改变如何参与仍不清楚。因此,在这项研究中,我们调查了越南结直肠癌(CRC)中 KRAS/NRAS/BRAF 突变的频率和分布,并探讨了 156 例 CRC 肿瘤中遗传和表观遗传异常之间的关系。通过 Cobas® KRAS Mutation Test、Therascreen NRAS Pyro Kit 和 Cobas® 4800 BRAF V600 Mutation Test 分别确定 KRAS(外显子 2,密码子 12/13;外显子 3,密码子 61)、NRAS(外显子 2,密码子 12/13;外显子 3,密码子 61)和 BRAF(外显子 15,密码子 600)的体细胞突变。通过甲基化特异性 PCR 检测 BRCA1、MLH1、MGMT、p16、RASSF1A 和 APC 的甲基化状态。还分析了每个异常在临床病理特征中的分布。结果表明,KRAS、NRAS 和 BRAF 的突变率分别为 41.0%、9.6%和 8.3%,而 BRCA1、MLH1、MGMT、p16、RASSF1A 和 APC 的甲基化率分别为 16.7%、16.7%、32.7%、30.1%、30.1%和 37.2%。KRAS 突变的分布与 CRC 中 NRAS(p<0.001)和 BRAF(p<0.001)突变相互排斥。RAS/RAF 突变在腺癌亚型中更为常见(p=0.020),而 RASSF1A 甲基化在粘液性腺癌亚型中更为频繁(p=0.007)。此外,在 MGMT(p=0.035)或 RASSF1A(p=0.043)甲基化病例中,KRAS 突变的频率明显高于无甲基化病例。BRAF 突变与 MLH1 高甲基化呈正相关(p=0.028),与 APC 高甲基化呈负相关(p=0.032)。总体而言,我们的结果表明遗传和表观遗传改变的特定相互作用,并表明 CRC 肿瘤发生中存在独立的致癌途径。